Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 6
2005 3
2006 2
2007 3
2008 1
2009 2
2010 6
2011 3
2012 6
2013 3
2014 9
2015 9
2016 9
2017 3
2018 10
2019 6
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

85 results
Results by year
Filters applied: . Clear all
Page 1
[Myasthenic Crisis].
Stetefeld HR, Schroeter M. Stetefeld HR, et al. Among authors: schroeter m. Fortschr Neurol Psychiatr. 2018 May;86(5):301-307. doi: 10.1055/a-0599-0811. Epub 2018 May 29. Fortschr Neurol Psychiatr. 2018. PMID: 29843179 Review. German.
Intravenous versus subcutaneous immunoglobulin - Authors' reply.
van Schaik IN, Mielke O; PATH study group. van Schaik IN, et al. Lancet Neurol. 2018 May;17(5):393-394. doi: 10.1016/S1474-4422(18)30109-1. Lancet Neurol. 2018. PMID: 29656738 No abstract available.
Osteopontin Augments M2 Microglia Response and Separates M1- and M2-Polarized Microglial Activation in Permanent Focal Cerebral Ischemia.
Ladwig A, Walter HL, Hucklenbroich J, Willuweit A, Langen KJ, Fink GR, Rueger MA, Schroeter M. Ladwig A, et al. Among authors: schroeter m. Mediators Inflamm. 2017;2017:7189421. doi: 10.1155/2017/7189421. Epub 2017 Sep 20. Mediators Inflamm. 2017. PMID: 29104378 Free PMC article.
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Metabolomic investigations in cerebrospinal fluid of Parkinson's disease.
Willkommen D, Lucio M, Moritz F, Forcisi S, Kanawati B, Smirnov KS, Schroeter M, Sigaroudi A, Schmitt-Kopplin P, Michalke B. Willkommen D, et al. Among authors: schroeter m. PLoS One. 2018 Dec 10;13(12):e0208752. doi: 10.1371/journal.pone.0208752. eCollection 2018. PLoS One. 2018. PMID: 30532185 Free PMC article.
Cis-4-[18F]fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism.
Sommerauer M, Galldiks N, Barbe MT, Stoffels G, Willuweit A, Coenen HH, Schroeter M, Timmermann L, Fink GR, Langen KJ. Sommerauer M, et al. Among authors: schroeter m. Nucl Med Commun. 2019 Apr;40(4):383-387. doi: 10.1097/MNM.0000000000000982. Nucl Med Commun. 2019. PMID: 30875335 Clinical Trial.
Transcranial Current Stimulation Alters the Expression of Immune-Mediating Genes.
Rabenstein M, Unverricht-Yeboah M, Keuters MH, Pikhovych A, Hucklenbroich J, Vay SU, Blaschke S, Ladwig A, Walter HL, Beiderbeck M, Fink GR, Schroeter M, Kriehuber R, Rueger MA. Rabenstein M, et al. Among authors: schroeter m. Front Cell Neurosci. 2019 Oct 25;13:461. doi: 10.3389/fncel.2019.00461. eCollection 2019. Front Cell Neurosci. 2019. PMID: 31708742 Free PMC article.
Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke.
Ladwig A, Rogall R, Hucklenbroich J, Willuweit A, Schoeneck M, Langen KJ, Fink GR, Rueger MA, Schroeter M. Ladwig A, et al. Among authors: schroeter m. J Neuroimmune Pharmacol. 2019 Jun;14(2):295-311. doi: 10.1007/s11481-018-9826-1. Epub 2018 Nov 28. J Neuroimmune Pharmacol. 2019. PMID: 30488353
Ocrelizumab initiation in patients with MS: A multicenter observational study.
Ellwardt E, Rolfes L, Klein J, Pape K, Ruck T, Wiendl H, Schroeter M, Zipp F, Meuth SG, Warnke C, Bittner S. Ellwardt E, et al. Among authors: schroeter m. Neurol Neuroimmunol Neuroinflamm. 2020 Apr 9;7(4):e719. doi: 10.1212/NXI.0000000000000719. Print 2020 Jul. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32273482 Free PMC article.
85 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback